180 Life Sciences (ATNF) | News Based Sentiment Analysis

• On September 20, 2025, ETHZilla deployed $100 million worth of Ethereum to EtherFi, a liquid restaking protocol, marking the company’s first venture into DeFi. This move aims to generate higher yields on its $456 million Ethereum holdings (as of August 31, 2025) and $221 million in cash equivalents, demonstrating a proactive treasury management strategy.
• ETHZilla actively managed its capital structure throughout September, repurchasing 6.0 million shares at an average price of $2.50 per share. A significant $80 million OTC transaction with Cumberland DRW, collateralized by ETH, funded this buyback, with $50 million drawn to date, reducing outstanding shares by 2.3% to 160,676,122 as of September 12, 2025.
• Following a substantial 98.87% increase over the prior 10 days, ETHZilla’s stock experienced an 8.1% decline on September 11, 2025, closing at $7.04 despite intraday fluctuations between $6.29 and $7.24. This volatility highlights the risks associated with the company’s ongoing transformation.
• Despite the stock dip, an analyst maintained a 'Strong Buy' rating for ETHZilla on September 13, 2025, with a price target of $11, representing a 0.00% increase from the current price at the time. This suggests continued optimism from some analysts regarding the company’s long-term potential.
• 180 Life Sciences Corp. (ATNF) received a “Strong Buy” rating from an analyst on September 21, 2025, with a $11 price target, while the stock closed at $7.04 on September 21, 2025, and $2.40 on September 22, 2025.
• Financial analysts projected 180 Life Sciences Corp.'s annual earnings for December 31, 2025, to be -$3.06 per share, and previously projected a revenue of $16.6 million for 2025 in February 2025.

The Investment Story: September was a month of strategic moves for ETHZilla, actively deploying its Ethereum holdings into DeFi and aggressively repurchasing shares, while 180 Life Sciences received a positive analyst rating despite facing projected losses.

What It Means for Investors: ETHZilla’s actions signal confidence in Ethereum and a commitment to shareholder value, but the stock’s volatility warrants caution. 180 Life Sciences’ “Strong Buy” rating presents potential upside, but investors should consider the projected negative earnings.

Looking Ahead: Investors should monitor ETHZilla’s progress in L2 deployment and Real World Asset tokenization, as well as the results of the upcoming earnings release estimated for Wednesday, November 12, 2025. For 180 Life Sciences, tracking revenue growth and earnings performance will be crucial.

The Bottom Line: Both companies are navigating evolving landscapes. ETHZilla is boldly transforming into an Ethereum treasury, while 180 Life Sciences aims for growth despite current financial projections. Investors should carefully assess the risks and potential rewards of each company.